A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei
- Author
- FARQUHARSO, A. L1 ; PRANES, N1 ; WITHAM, G1 ; SWINDELL, R2 ; TAYLOR, M. B3 ; RENEHAN, A. G1 4 ; ROUT, S1 ; WILSON, M. S1 ; O'DWYER, S. T1 ; SAUNDERS, M. P4 5
[1] Peritoneal Tumour Service, Department of Surgery, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
[2] Department of Medical Statistics, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
[3] Department of Radiology, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
[4] School of Cancer and Imaging Sciences, University of Manchester, Manchester, United Kingdom
[5] Department of Clinical Oncology, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom - Source
British journal of cancer. 2008, Vol 99, Num 4, pp 591-596, 6 p ; ref : 3/4 p
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- capecitabine chemotherapy mitomycin C pseudomyxoma peritonei
- Keyword (fr)
- Anticancéreux Cancérologie Capécitabine Chimiothérapie Essai clinique phase II Homme Inopérable Maladie gélatineuse du péritoine Mitomycine Promédicament Simultané Stade avancé Traitement Agent alkylant Ascite Dérivé de la fluoropyrimidine Pathologie de l'abdomen Pyrimidine nucléoside
- Keyword (en)
- Antineoplastic agent Cancerology Capecitabine Chemotherapy Phase II trial Human Unresectable Pseudomyxoma peritonei Mitomycin Prodrug Concurrent Advanced stage Treatment Alkylating agent Ascites Fluoropyrimidine derivatives Abdominal disease Pyrimidine nucleoside
- Keyword (es)
- Anticanceroso Cancerología Capecitabina Quimioterapia Ensayo clínico fase II Hombre Inoperable Pseudomixoma peritoneal Mitomicina Promedicamento Simultáneo Estadio avanzado Tratamiento Agente alquilante Ascitis Fluoropirimidina derivado Abdomen patología Pirimidina nucleósido
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13D Abdomen / 002B13D03 Other diseases. Semiology
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20656329
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjc.6604522 
https://dx.doi.org/10.1038/sj.bjc.6604522
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604522\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"591\";s:8:\"\u0000*\u0000epage\";s:3:\"596\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FARQUHARSO\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:9:\"PRANES, N\";i:1;s:9:\"WITHAM, G\";i:2;s:11:\"SWINDELL, R\";i:3;s:12:\"TAYLOR, M. B\";i:4;s:13:\"RENEHAN, A. G\";i:5;s:7:\"ROUT, S\";i:6;s:12:\"WILSON, M. S\";i:7;s:13:\"O'DWYER, S. T\";i:8;s:14:\"SAUNDERS, M. P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604522\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"591\";s:8:\"\u0000*\u0000epage\";s:3:\"596\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FARQUHARSO\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:9:\"PRANES, N\";i:1;s:9:\"WITHAM, G\";i:2;s:11:\"SWINDELL, R\";i:3;s:12:\"TAYLOR, M. B\";i:4;s:13:\"RENEHAN, A. G\";i:5;s:7:\"ROUT, S\";i:6;s:12:\"WILSON, M. S\";i:7;s:13:\"O'DWYER, S. T\";i:8;s:14:\"SAUNDERS, M. P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604522\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604522\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"591\";s:8:\"\u0000*\u0000epage\";s:3:\"596\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FARQUHARSO\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:9:\"PRANES, N\";i:1;s:9:\"WITHAM, G\";i:2;s:11:\"SWINDELL, R\";i:3;s:12:\"TAYLOR, M. B\";i:4;s:13:\"RENEHAN, A. G\";i:5;s:7:\"ROUT, S\";i:6;s:12:\"WILSON, M. S\";i:7;s:13:\"O'DWYER, S. T\";i:8;s:14:\"SAUNDERS, M. P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604522\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"591\";s:8:\"\u0000*\u0000epage\";s:3:\"596\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FARQUHARSO\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:9:\"PRANES, N\";i:1;s:9:\"WITHAM, G\";i:2;s:11:\"SWINDELL, R\";i:3;s:12:\"TAYLOR, M. B\";i:4;s:13:\"RENEHAN, A. G\";i:5;s:7:\"ROUT, S\";i:6;s:12:\"WILSON, M. S\";i:7;s:13:\"O'DWYER, S. T\";i:8;s:14:\"SAUNDERS, M. P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604522\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"591\";s:8:\"\u0000*\u0000epage\";s:3:\"596\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FARQUHARSO\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:9:\"PRANES, N\";i:1;s:9:\"WITHAM, G\";i:2;s:11:\"SWINDELL, R\";i:3;s:12:\"TAYLOR, M. B\";i:4;s:13:\"RENEHAN, A. G\";i:5;s:7:\"ROUT, S\";i:6;s:12:\"WILSON, M. S\";i:7;s:13:\"O'DWYER, S. T\";i:8;s:14:\"SAUNDERS, M. P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
